JP2016537010A - 予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット - Google Patents

予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット Download PDF

Info

Publication number
JP2016537010A
JP2016537010A JP2016540920A JP2016540920A JP2016537010A JP 2016537010 A JP2016537010 A JP 2016537010A JP 2016540920 A JP2016540920 A JP 2016540920A JP 2016540920 A JP2016540920 A JP 2016540920A JP 2016537010 A JP2016537010 A JP 2016537010A
Authority
JP
Japan
Prior art keywords
subject
breast cancer
luminal
subtype
recurrence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016540920A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537010A5 (enExample
Inventor
チョン ユー．チャン マギー
チョン ユー．チャン マギー
オー．ニールセン トーステン
オー．ニールセン トーステン
エム．ペルー チャールズ
エム．ペルー チャールズ
ジェイ．エリス マシュー
ジェイ．エリス マシュー
エス．バーナード フィリップ
エス．バーナード フィリップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of JP2016537010A publication Critical patent/JP2016537010A/ja
Publication of JP2016537010A5 publication Critical patent/JP2016537010A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2016540920A 2013-09-09 2014-09-09 予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット Pending JP2016537010A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361875373P 2013-09-09 2013-09-09
US61/875,373 2013-09-09
US201461990948P 2014-05-09 2014-05-09
US61/990,948 2014-05-09
PCT/US2014/054760 WO2015035377A1 (en) 2013-09-09 2014-09-09 Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy

Publications (2)

Publication Number Publication Date
JP2016537010A true JP2016537010A (ja) 2016-12-01
JP2016537010A5 JP2016537010A5 (enExample) 2017-09-14

Family

ID=51688397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540920A Pending JP2016537010A (ja) 2013-09-09 2014-09-09 予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット

Country Status (7)

Country Link
US (1) US20150072021A1 (enExample)
EP (1) EP3044332A1 (enExample)
JP (1) JP2016537010A (enExample)
AU (1) AU2014317843A1 (enExample)
CA (1) CA2923166A1 (enExample)
IL (1) IL244421A0 (enExample)
WO (1) WO2015035377A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023535811A (ja) * 2020-07-28 2023-08-21 ホスピタル クリニック デ バルセロナ ＨＥＲ２陽性乳癌を患う患者の予後診断を行うｉｎ ｖｉｔｒｏ方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
PL2297359T4 (pl) 2008-05-30 2014-07-31 Univ North Carolina Chapel Hill Profile ekspresji genów do przewidywania skutków raka piersi
SG11201704177SA (en) 2014-11-24 2017-06-29 Nanostring Technologies Inc Methods and apparatuses for gene purification and imaging
JP2018500895A (ja) * 2014-12-09 2018-01-18 キングス・カレッジ・ロンドン タキサン療法による乳癌治療
MX2018005867A (es) * 2015-11-13 2018-09-21 Biotheranostics Inc Integracion de las caracteristicas tumorales con el indice de cancer de mama.
KR102456433B1 (ko) 2016-03-02 2022-10-19 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
CN107574243B (zh) * 2016-06-30 2021-06-29 博奥生物集团有限公司 分子标志物、内参基因及其应用、检测试剂盒以及检测模型的构建方法
CN108456730B (zh) * 2018-02-27 2021-01-05 海门善准生物科技有限公司 一种复发风险基因群作为标志物在制备评估乳腺癌分子分型内远处复发风险的产品中的应用
US12352750B2 (en) 2019-04-04 2025-07-08 University Of Utah Research Foundation Multigene assay to assess risk of recurrence of cancer
KR102414754B1 (ko) * 2019-10-10 2022-06-30 주식회사 종근당 직장암 항암화학방사선 치료 반응 예측용 바이오마커
TW202129008A (zh) * 2019-11-05 2021-08-01 香港商行動基因（智財）有限公司 檢測異檸檬酸脫氫酶突變的套組及方法
CN113278700B (zh) * 2021-06-04 2022-08-09 浙江省肿瘤医院 一种用于乳腺癌分型及预后预测的引物组及试剂盒
KR20240081508A (ko) 2022-11-17 2024-06-10 인제대학교 산학협력단 Dna 메틸화 변화를 통한 방사선치료 반응성 예측용 바이오마커 조성물 및 이의 용도
CN116622885B (zh) * 2023-05-23 2025-01-10 福建省农业科学院果树研究所 一种用于不同桃花色鉴定的分子标记方法及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084992A2 (en) * 2006-01-19 2007-07-26 The University Of Chicago Prognosis and therapy predictive markers and methods of use
JP2010538609A (ja) * 2007-09-06 2010-12-16 バイオセラノスティクス，インコーポレイティド 腫瘍グレード分類と癌の予後診断
JP2010539890A (ja) * 2007-09-14 2010-12-24 ユニヴァーシティ オブ サウス フロリダ 放射線治療の応答を予測するための遺伝子シグネチャー
JP2011524162A (ja) * 2008-05-30 2011-09-01 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル 乳癌の予後を予測するための遺伝子発現プロフィール

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
AU675054B2 (en) 1991-11-22 1997-01-23 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
WO2006010150A2 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
JP5700911B2 (ja) 2005-12-23 2015-04-15 ナノストリング テクノロジーズ，インコーポレーテッド 配向され、固定化された巨大分子を含む組成物とその製造法
EP1963531B1 (en) 2005-12-23 2011-09-21 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
CA2687292C (en) 2007-04-10 2017-07-04 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
ES2614810T3 (es) 2008-08-14 2017-06-02 Nanostring Technologies, Inc Nanoindicadores estables
EP2785873A4 (en) * 2011-11-30 2015-11-11 Univ North Carolina METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY
IN2014MN02418A (enExample) * 2012-05-22 2015-08-14 Nanostring Technologies Inc

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084992A2 (en) * 2006-01-19 2007-07-26 The University Of Chicago Prognosis and therapy predictive markers and methods of use
JP2010538609A (ja) * 2007-09-06 2010-12-16 バイオセラノスティクス，インコーポレイティド 腫瘍グレード分類と癌の予後診断
JP2010539890A (ja) * 2007-09-14 2010-12-24 ユニヴァーシティ オブ サウス フロリダ 放射線治療の応答を予測するための遺伝子シグネチャー
JP2011524162A (ja) * 2008-05-30 2011-09-01 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル 乳癌の予後を予測するための遺伝子発現プロフィール

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. CLIN. ONCOL., 2009年, vol. 27, no. 8, JPN6018026942, pages 1160 - 1167, ISSN: 0003839437 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023535811A (ja) * 2020-07-28 2023-08-21 ホスピタル クリニック デ バルセロナ ＨＥＲ２陽性乳癌を患う患者の予後診断を行うｉｎ ｖｉｔｒｏ方法

Also Published As

Publication number Publication date
AU2014317843A1 (en) 2016-03-24
IL244421A0 (en) 2016-04-21
US20150072021A1 (en) 2015-03-12
EP3044332A1 (en) 2016-07-20
WO2015035377A1 (en) 2015-03-12
CA2923166A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
US20230272476A1 (en) Nano46 genes and methods to predict breast cancer outcome
JP2016537010A (ja) 予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット
JP5971769B2 (ja) アントラサイクリン療法を用いて乳癌を処置する方法
JP6144695B2 (ja) タキサン療法を用いて乳癌を処置する方法
US20140037620A1 (en) Methods of Treating Breast Cancer with Gemcitabine Therapy
KR20230011905A (ko) 파노믹 게놈 유병률 점수
US20140154681A1 (en) Methods to Predict Breast Cancer Outcome
JP2016519935A (ja) 結節陽性の初期乳癌における再発リスクを予測する方法
US20160160293A1 (en) Breast cancer treatment with taxane therapy
WO2010003772A1 (en) Method for predicting adverse response to erythropoietin in breast cancer treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190305